The upcoming meeting, taking place on November 10 at Mila, will explore how we can collectively develop, govern, and deploy high-performing, reliable, and secure agentic systems by connecting academic researchers, industry experts, and practitioners.
Join us on the Venture Scientist Bootcamp, a full time, 4-month incubator at Mila, built specifically for deep tech founders with elite STEM backgrounds. You have until November 21, 2026 to apply!
We use cookies to analyze the browsing and usage of our website and to personalize your experience. You can disable these technologies at any time, but this may limit certain functionalities of the site. Read our Privacy Policy for more information.
Setting cookies
You can enable and disable the types of cookies you wish to accept. However certain choices you make could affect the services offered on our sites (e.g. suggestions, personalised ads, etc.).
Essential cookies
These cookies are necessary for the operation of the site and cannot be deactivated. (Still active)
Analytics cookies
Do you accept the use of cookies to measure the audience of our sites?
Multimedia Player
Do you accept the use of cookies to display and allow you to watch the video content hosted by our partners (YouTube, etc.)?
Revisiting the genetic support of leukotriene pathway drug targets in atherosclerotic cardiovascular disease
Tristan St-Laurent
Julien St.-Pierre
Julien Quang Le Van
Marc‐André Legault
Arachidonate 5-lipoxygenase (5-LO) and its activating protein, encoded by ALOX5 and ALOX5AP respectively, are two leukotriene pathway protei… (see more)ns suspected to play a role in atherosclerotic cardiovascular disease (ASCVD) through inflammatory mechanisms. Prior genetic association studies linking ALOX5 and ALOX5AP to ASCVD have motivated clinical trials of 5-LO inhibitors, such as atreleuton, which was associated with reduced atherosclerotic plaque progression in patients with a recent acute coronary syndrome in a phase II trial. However, the effect of 5-LO inhibition on ASCVD clinical outcomes remains unclear. Using data from the UK Biobank, we revisit previously reported genetic associations of ALOX5 and ALOX5AP with ASCVD using a multi-ancestry meta-analysis including data from 378,962 participants. We characterize ancestral differences in previously studied ALOX5 and ALOX5AP polymorphisms which could have led to population stratification. When adequately accounting for ancestry, these previous associations were not replicated. In addition to our replication efforts, we used association scans and transcriptome-wide association studies to test the involvement of leukotriene pathway genes with ASCVD. Overall, our results do not support a role for genetic variation in ALOX5 or its activating protein in ASCVD risk.
In Mendelian randomization (MR) studies, genetic variants are used as instrumental variables (IVs) to investigate causal relationships betwe… (see more)en exposures and outcomes based on observational data. However, numerous genetic studies have shown the pervasive pleiotropy of genetic variants, meaning that many, if not most, variants are associated with multiple traits, potentially violating the core assumptions of IV estimation. Uncorrelated pleiotropy occurs when genetic variants have a direct effect on the outcome that is not mediated by the exposure, while correlated pleiotropy occurs when genetic variants affect the exposure and outcome via shared heritable confounders. In this work, we propose a novel MR method, called MR-Quantile, based on weighted quantile regression (WQR) that is robust to both correlated and uncorrelated pleiotropy. We propose a procedure for selecting the optimal quantile of the ratio estimates through a likelihood-based formulation of WQR using the asymmetric Laplace distribution. Monte Carlo simulations demonstrate the empirical performance of the proposed method, especially in settings with many invalid IVs with weak pleiotropic effects. Finally, we apply our method to study the causal effect of resting heart rate on atrial fibrillation. Genetic variants associated with heart rate were identified in a genome-wide association study of 425,748 individuals from the VA Million Veteran Program, and used as instruments in a two-sample MR analysis with summary statistics from a genetic meta-analysis of 228,926 AF cases across eight studies.